CROSS COUNTRY HEALTHCARE INC (CCRN): Completion of Acquisition or Disposition of Assets
CROSS COUNTRY HEALTHCARE INC (CCRN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false --12-31 0001141103 0001141103 2026-07-21 2026-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ Form 8-K ____________________________ Current Report Pursuant to Sectio
How this was made
The 30-second read
Why it matters
At the effective time, each outstanding share converts into $13.25 cash, and the company terminates its ABL credit agreement obligations and credit commitments. The filing also documents Nasdaq trading suspension and steps toward delisting and termination of Exchange Act reporting.
Market read
Deal close mechanics (cash conversion, credit agreement termination, and Nasdaq suspension/delisting steps) are the primary near-term trading drivers for CCRN.
What to watch
Traders should watch for any remaining procedural items (Form 25/15 effectiveness timing, any appraisal rights outcomes) that can affect liquidity and residual volatility even after the merger close.
Background
The 8-K reports the completion of a previously announced merger agreement dated May 6, 2026, with Cross Country Healthcare surviving as a wholly-owned subsidiary of the parent.
Ticker impact
Cross Country Healthcare completed its merger, converting each share into $13.25 cash and terminating its ABL credit agreement at closing.
Likely limited upside after deal close; volatility may persist around delisting/registration termination mechanics and any remaining appraisal or settlement-related items.
The filing states the merger effective time consideration ($13.25 per share), termination of the ABL credit agreement, and Nasdaq trading suspension/removal process, all of which are immediate, deal-specific drivers for the stock.
Market effects
Minimal sector read-through; this is primarily a single-company deal completion and delisting process.
No clear regional spillover beyond US healthcare staffing M&A activity.
Low global relevance; transaction is domestic and deal-specific.
Counterpoint
If the market had priced in a higher probability of delay or different consideration, the confirmed $13.25 close could still support a short-term relief bid despite delisting.
Key entities
- public_companyCross Country Healthcare, Inc.
Subject of the merger completion and cash consideration conversion at the effective time.
- acquirerKL Criss Cross Intermediate, LLC
Parent entity in the merger agreement.
- acquirer_subKL Criss Cross Merger Sub, Inc.
Merger subsidiary that merged into Cross Country Healthcare.
- lenderWells Fargo Bank, National Association
Administrative and collateral agent under the ABL Credit Agreement that was terminated at closing.
- venueNasdaq Stock Market LLC
Requested suspension of trading and removal from listing prior to the July 21, 2026 open.
